Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.350
-0.160 (-3.55%)
At close: Mar 24, 2026, 4:00 PM EDT
4.430
+0.080 (1.84%)
After-hours: Mar 24, 2026, 4:10 PM EDT
Molecular Partners AG Employees
Molecular Partners AG had 134 employees as of December 31, 2025. The number of employees decreased by 25 or -15.46% compared to the previous year.
Employees
134
Change
-25
Growth
-15.46%
Revenue / Employee
n/a
Profits / Employee
-$580,216
Market Cap
162.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 134 | -25 | -15.46% |
| Jun 30, 2025 | 153 | -9 | -5.50% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Jun 30, 2024 | 162 | -7 | -3.92% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Jun 30, 2023 | 169 | 5 | 2.74% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Jun 30, 2022 | 164 | 12 | 7.89% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Mar 31, 2021 | 152 | 17 | 12.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ProQR Therapeutics | 187 |
| Immunic | 92 |
| Cartesian Therapeutics | 75 |
| Tenaya Therapeutics | 70 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Fennec Pharmaceuticals | 32 |
MOLN News
- 1 day ago - Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewsWire
- 5 days ago - Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes - GlobeNewsWire
- 7 days ago - Molecular Partners to Hold Three Poster Presentations at AACR 2026 - GlobeNewsWire
- 12 days ago - Molecular Partners Reports Highlights and Financial Results for Full Year 2025 - GlobeNewsWire
- 26 days ago - Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 - GlobeNewsWire
- 3 months ago - Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire